Navigation Links
Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium
Date:12/9/2010

with gemcitabine and carboplatin in the MDA-MB-468 (-) Triple Negative Breast Cancer (TNBC) cell lineIniparib Data:Abstract # P6-15-01

Gene pathway analysis of

primary TNBC tumors

Sunday, Dec. 12

7:00 - 8:30 AM CSTData from a preclinical study characterizing the pathways of  primary human triple-negative breast cancersAbout Iniparib (BSI 201)Iniparib (BSI-201), the United States Adopted Name (USAN) for BSI-201, is a novel investigational small molecule with poly (ADP-ribose) polymerase (PARP) inhibitory activity.

BiPar Sciences and sanofi-aventis are pursuing a broad development program with iniparib in breast cancer and multiple trials are planned to start in the next several months.  A Phase 3 trial in mTNBC is ongoing, and multiple new trials are planned to start in the next several months.  New trials include:

  • A Phase 2 trial in HER2-/Hormone receptor positive (ER+ and/or PR+) metastatic breast cancer
  • A Phase 1b/2 trial in HER2- metastatic breast cancer (combination with taxane chemotherapy)
  • A Phase 2 trial in mTNBC testing the Taxotere/Cytoxan chemotherapy combination

    • Iniparib also in being studied in a Phase 3 trial for patients with squamous non-small cell lung cancer, and in Phase 2 trials for patients with ovarian, uterine and brain cancers.  The regulatory submissions are planned for Q1 2011 in the U.S. and Q2 2011 in the European Union.  

    About Taxotere (docetaxel) Injection ConcentrateIntroduced more than 14 years ago, Taxotere is approved for use in the following indications:

    Breast Cancer:  

  • TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy
  • TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer

    • Non-Small Cell L
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
    2. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
    3. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
    4. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
    5. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
    6. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
    7. European Hospital Anticoagulant Market Dominated by Sanofi-Aventiss Clexane
    8. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    9. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
    10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
    11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
    (Date:5/17/2013)... NATICK, Mass. , May 17, 2013  Boston ... to participate at the annual EuroPCR Scientific Program May ... "We are pleased to present a particularly rich and ... Keith Dawkins , M.D., global chief ... several trials will be presented, including the NG PROMUS ...
    (Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
    Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
    ... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... devices worldwide, announced today its selected unaudited financial results for ... Highlights for Second Quarter 2011 ... 21.2% over the second quarter of 2010. Robust ...
    ... Pharmaceutical Company ("the Company," "K-V") (NYSE: KVa/KVb) today announced ... of assets of Nesher Pharmaceuticals, Inc. ("Nesher"), the Company,s ... assets to Zydus Pharmaceuticals (USA), Inc and Zynesher Pharmaceuticals ... sales price for the transaction is $60 million (subject ...
    Cached Medicine Technology:Mindray Announces Second Quarter 2011 Financial Results 2Mindray Announces Second Quarter 2011 Financial Results 3Mindray Announces Second Quarter 2011 Financial Results 4Mindray Announces Second Quarter 2011 Financial Results 5Mindray Announces Second Quarter 2011 Financial Results 6Mindray Announces Second Quarter 2011 Financial Results 7Mindray Announces Second Quarter 2011 Financial Results 8Mindray Announces Second Quarter 2011 Financial Results 9Mindray Announces Second Quarter 2011 Financial Results 10Mindray Announces Second Quarter 2011 Financial Results 11Mindray Announces Second Quarter 2011 Financial Results 12Mindray Announces Second Quarter 2011 Financial Results 13Mindray Announces Second Quarter 2011 Financial Results 14Mindray Announces Second Quarter 2011 Financial Results 15Mindray Announces Second Quarter 2011 Financial Results 16Mindray Announces Second Quarter 2011 Financial Results 17K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 2K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 3K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 4K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 5K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 6K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 7K-V Pharmaceutical Company Announces the Completion of the Sale of Nesher Pharmaceuticals, Inc. its Generic Pharmaceutical Business 8
    (Date:5/20/2013)... Senior Solutions Management Group (SSMG), a leading provider ... announced that four of its Resident Assistants from several ... received The Caring Heart Award from Alzheimer’s Tennessee. ... Braden from River Oaks Place in Loudon, Mary Gibson ... McCormick from Wellspring Senior Living in Knoxville all accepted ...
    (Date:5/20/2013)... May 20, 2013 Adding more vegetables to ... done to drastically improve health. Vegetables have been shown ... cancer. , The amount of vegetables that should ... and age. One way to find out the recommended ... tool from the Center for Disease Control. ...
    (Date:5/20/2013)... NJ (PRWEB) May 20, 2013 ... recovery services to healthcare organizations, is pleased to ... Alabama has selected the company to assist in ... . , Under Medicare reimbursement regulations, when certain ... discharging hospital is paid at a reduced rate. ...
    (Date:5/20/2013)... (PRWEB) May 20, 2013 AlignLife of ... 2013 race series sponsor of the Tri-4-Schools children’s triathlon. ... as a platform to get kids active and fight ... setting and achieving goals, fitness, nutrition, sportsmanship and self-confidence. ... lifestyle in children ages 14 and under so they ...
    (Date:5/20/2013)... Los Angeles, CA (PRWEB) May 20, 2013 ... 2013) – MessageSolution, an industry leader in enterprise-class ... of MessageSolution Enterprise eDiscovery Platform 7.0, the latest ... to address all facets of the legal discovery ... May 21-22 in Los Angeles CA. , As ...
    Breaking Medicine News(10 mins):Health News:Senior Solutions Management Caregivers Receive Caring Heart Award From Alzheimer’s Tennessee 2Health News:Flax Seasoning Shows How Eating More Vegetables Will Improve Health 2Health News:Southeast Alabama Medical Center Selects BESLER Consulting’s Transfer DRG Revenue Recovery Service 2Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 2Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 3Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 4
    ... updates the NCCN Guidelines for Non-Small Cell Lung Cancer to ... specific patients with Non-Small Cell Lung Cancer, and a revised ... National Comprehensive Cancer Network (NCCN) recently updated the ... a new section about maintenance therapy, a number of new ...
    ... Convention and Preconvention Program, the only medical imaging conference ... medical ultrasound, to be held March 24-27, 2010, in ... emerging applications and unique opportunities for collaboration between physicians, ... and expand into new arenas. With a ...
    ... the number of children diagnosed with autistic spectrum disorders over ... have found a sharp difference between the beliefs of ordinary ... incidence of autism. Expert consensus is that the rapid ... many lay people directly or indirectly affected by the disorder ...
    ... Group evaluated the achievements at EU level in combating ... EU cannot turn its back on CVD", expressed Dirk ... the MEP Heart Group. There is overwhelming evidence that ... It is therefore the task of decision makers at ...
    ... of vitamin E in the nuts, expert says , WEDNESDAY, ... reduce your risk for lung cancer and other malignancies, according ... of a type of vitamin E called gamma-tocopherol. , "It ... against certain forms of cancer. Higher intakes of gamma-tocopherol ... ...
    ... CORD:USE Cord Blood Bank is proud to announce that ... Department of Health and Human Services has awarded CORD:USE Cord ... supply of cord blood units for the National Cord Blood ... a prestigious designation which further validates the procedures and operations ...
    Cached Medicine News:Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 2Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 3Health News:AIUM gears up for 2010 Annual Convention in San Diego, Calif. 2Health News:People affected by autism believe increase is 'real,' not diagnostic 2Health News:Want to Cut Cancer Risk? Try Munching Pistachios 2Health News:CORD:USE Cord Blood Bank Receives Grant From HRSA to Increase the National Cord Blood Inventory 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    Medicine Products: